Immutep Limited

Immutep Limited has achieved a key clinical milestone with the successful dosing of the first patient in its TACTI-004 Phase III trial, aimed at tackling advanced non-small cell lung cancer (NSCLC). This pivotal moment not only underscores the company's commitment to advancing innovative treatment options but also highlights the trial's potential to redefine standard care. With approximately 756 patients to be enrolled across over 150 clinical sites globally, this initiative stands to gather extensive data that can drive future marketing approvals. The unique action mechanism of Immutep’s eftilagimod alfa may position it as a front-runner in the burgeoning immunotherapy segment, addressing significant unmet needs within oncology. Read More https://lnkd.in/gARtNcf8 Click here to read the full ASX announcement https://lnkd.in/gDMspD-g, #Tacti004, #NSCLC, #immunotherapy, #clinicalTrials

The first patient in our TACTI-004 lung cancer trial has been safely dosed in Australia, marking a significant milestone for the team at Immutep Limited! TACTI-004 is our global Phase III clinical trial of our lead product candidate, efti in combination with MSD’s KEYTRUDA. It will enrol approximately 756 patients at more than 150 clinical sites across the world. Importantly, trial results will inform a potential marketing approval application for efti in non-small cell lung cancer, one of the largest indications in oncology. Read: https://bit.ly/4j2hd86 #efti #oncology #clinicaltrial #NSCLC

We are pleased to share that our pivotal TACTI-004 Phase III trial has been selected for an upcoming poster presentation at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster will include an overview and study design of the TACTI-004 Phase III evaluating efti in combination with MSD’s KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer. This global trial is actively recruiting patients, and will enroll approximately 750 patients at over 150 clinical sites in over 25 countries. The poster will be available on our website after the presentation on 26 March at 13:50 CET. Read more: https://bit.ly/4hi5Uax #efti #oncology #clinicaltrial #NSCLC

In the third episode of the six-part immunotherapy series with ShareCafe, Immutep Limited CEO Marc Voigt explores the complexities of treating autoimmune diseases and how Immutep’s #IMP761 targets the root cause by regulating overactive T-cells. With an estimated 50 million people affected by autoimmune diseases globally, immunotherapies hold significant potential to improve patient outcomes and reshape the treatment landscape. Watch: https://bit.ly/4bKutLV #Immunotherapy #AutoimmuneDisease

As part of his recent trip to see shareholders in Australia last week, Immutep Limited CEO Marc Voigt joined ShareCafe to talk about the Company’s latest advancements in its phase III clinical trial in lung cancer, which is expected to dose its first patient this month, along with other trials and upcoming milestones. Watch the full interview: https://bit.ly/4hiJh5C #biotechnology #immunotherapy #oncology #NSCLC #autoimmunedisease #LAG3

In episode 2 of our series with ShareCafe, Immutep Limited CEO Marc Voigt explores the complexities of cancer treatment and the expanding role of immuno-oncology. With a strong safety profile, Immutep’s lead candidate shows promise in combination therapies, driving progress in cancer care. Watch here: https://bit.ly/4ip3MPg #biotechnology #LAG3 #oncology #immunotherapy

In the first episode of a six-part series with ShareCafe, Immutep Limited CEO Marc Voigt discusses the rapid rise of immunotherapy and its growing impact on cancer treatment. With a Phase 3 lead candidate and key partnerships, Immutep is driving innovation in this expanding $189B market. Watch the interview: https://bit.ly/3Xjamyv #Biotechnology #LAG3 #Oncology #Immunotherapy

Immutep Limited is pleased to share its half-year report for the period ended 31 December 2024. Throughout the half-year, the Company has made significant progress and reported encouraging clinical results. With the commencement of the TACTI-004 trial, Immutep has advanced to become a Phase III-stage biotech company, with a portfolio of promising assets.   Read here: https://bit.ly/3QCnET1   #biotechnology #oncology #LAG3

CEO Marc Voigt recently caught up with ShareCafe to discuss Immutep Limited’s encouraging progress with #efti. Listen here: https://bit.ly/3CXhCcv #NSCLC #biotechnology #oncology

Immutep's therapies move towards late-stage development. More here: https://lnkd.in/gTE-AqPt